Home Products Antibodies Primary Antibodies 01 676 653
01-676-653

IL-27 p28 Polyclonal Antibody, Invitrogen™

Manufacturer: Thermo Scientific

Select a Size

Pack Size SKU Availability Price
Each of 1 01-676-653-Each-of-1 In Stock ₹ 46,502.50

01-676-653 - Each of 1

₹ 46,502.50

In Stock

Quantity

1

Base Price: ₹ 46,502.50

GST (18%): ₹ 8,370.45

Total Price: ₹ 54,872.95

Antigen

IL-27 p28

Classification

Polyclonal

Conjugate

Unconjugated

Gene

Il27

Gene Alias

IL27; IL-27; IL-27 p28 subunit; IL-27 subunit alpha; Il27a; IL-27A; IL-27-A; IL27-A; IL27p28; IL-27p28; IL30; IL-30; ILN; Interleukin; interleukin 27; interleukin 30; Interleukin-27; interleukin-27 subunit alpha; Interleukin-30; p28

Host Species

Rabbit

Purification Method

Protein G

Regulatory Status

RUO

Gene ID (Entrez)

246778, 246779

Content And Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Form

Liquid

Applications

Immunocytochemistry, Western Blot

Concentration

0.5 mg/mL

Formulation

PBS with 0.05% BSA and 0.05% sodium azide

Gene Accession No.

Q8K3I6, Q8NEV9

Gene Symbols

Il27

Immunogen

Synthetic peptide corresponding to amino acids 31-46 (RPPGRPQLSLQELRRE) of human IL-27 (p28 subunit)

Quantity

100 μg

Primary or Secondary

Primary

Target Species

Human, Mouse

Product Type

Antibody

Isotype

IgG

Description

  • Suggested positive control: Jurkat, NIH-3T3
  • IL-27, a member of the IL-12 family, is a heterodimeric protein consisting of the p40-related protein Epstein-Barr virus-induced gene 3 (EBI3) non-covalently linked to an IL-12p35-related protein, p28 (also known as IL-30)
  • IL-27 is produced by activated APCs and mature dendritic cells
  • IL-27 exerts its activities on NK cells and naive CD4+ T cells; mRNA expression analysis of IL-27 receptor components (WSX-1/TCCR and gp130) suggests that IL-27 may also target other cells, including mast cells and monocytes
  • Binding of IL-27 to WSX-1/gp130 activates JAK1, STAT1, and STAT3 and STAT1/3 phosphorylation
  • WSX-1/TCCR-deficient mice develop impaired Th1 responses and are more susceptible to infection with L
  • monocytogenes suggesting that Th1 responses require IL-27
  • Although activation of WSX-1 is required for the initiation of Th1 responses, it is not necessary for maintaining Th1 responses
  • IL-27 alone is not able to induce the differentiation of CD4+ T cells into IFN-γ-producing cells, suggesting a role for IL-27 as an initial activator of Th1 responses
  • An important effect of IL-27 in initiating Th1 responses is the induction of the Th1-specific transcription factor T-bet as well as the suppression of the Th2-specific transcription factor GATA-3
  • T-bet plays a critical role in Th1 differentiation by its ability to maintain IL-12Rβ2 expression following CD4+ T cell activation
  • Recent studies indicate that IL-27 has a potent antitumor activity
  • In vitro, IL-27 has been found to act directly on naive CD8 cells, generating CTL with enhanced granzyme B expression
  • In vivo, IL-27 has been reported to augment CTL activity, inhibit tumor growth, and induce complete regression of primary and metastatic neuroblastoma tumors.